UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000034081
Receipt No. R000038854
Scientific Title An investigator-initiated phase I/IIa trial of subretinal injection of DVC1-0401 as neuroprotective gene therapy for retinitis pigmentosa
Date of disclosure of the study information 2018/11/01
Last modified on 2019/02/14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title An investigator-initiated phase I/IIa trial of subretinal injection of DVC1-0401 as neuroprotective gene therapy for retinitis pigmentosa
Acronym An investigator-initiated trial of DVC1-0401 as gene therapy for retinitis pigmentosa
Scientific Title An investigator-initiated phase I/IIa trial of subretinal injection of DVC1-0401 as neuroprotective gene therapy for retinitis pigmentosa
Scientific Title:Acronym An investigator-initiated trial of DVC1-0401 as gene therapy for retinitis pigmentosa
Region
Japan

Condition
Condition Retinitis pigmentosa
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 For patients with retinitis pigmentosa accompanied with decreased central retinal sensitivity,
1) To examine safety of subretinal injection of DVC1-0401
2) To explore the inhibitory effect on declining visual function
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase I,II

Assessment
Primary outcomes Incidence of adverse events
Key secondary outcomes 1) Rate of change of the mean retinal sensitivity (central 12 points)
: Primary outcome measure of efficiency
2) Rate of change of the mean retinal sensitivity (central 4 points)
: Secondary outcome measure of efficiency-1
3) Rate of change of the visual acuity (logMAR converted value)
: Secondary outcome measure of efficiency-2
4) Amount of hPEDF protein in the aqueous humor
: Exploratory outcome measure

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control No treatment
Stratification NO
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment No need to know

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Gene
Interventions/Control_1 Subretinal injection of low-dose DCV1-0401 (Simian immunodeficiency virus vector expressing human pigment epithelium-derived factor (hPEDF))
Interventions/Control_2 Subretinal injection of medium-dose DCV1-0401
Interventions/Control_3 Subretinal injection of high-dose DCV1-0401
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria 1) Subjects with retinitis pigmentosa diagnosed by two or more ophthalmic specialists
2) 40 years and above, and 70 years or younger
3) The mean retinal sensitivity measured by Humphrey perimeter (10-2 program) is less than 30 dB (central 4 points)
4) Interocular difference in visual acuity is less than or equal to 0.21 (logMAR converted value)
5) Interocular difference in visual field is less than or equal to twofold (Goldmann perimeter V-4e)
6) Interocular difference in the MD value measured by Humphrey perimeter (10-2 program) is less than or equal to 5 dB
7) Interocular difference in central retinal thickness measured by optical coherence tomography is less than or equal to 50 um
8) No interocular difference in the structure of outer retinal layer (ellipsoid zone) observed by optical coherence tomography
9) In case of subjects who are followed up over three years, interocular difference in the rate of change of visual acuity (logMAR converted value) and the MD value measured by Humphrey perimeter (10-2 program) is less than or equal to twofold
10) Difference in the mean retinal sensitivity measured in repeating tests using Humphrey perimeter (10-2 program) within 60 days before administration is binocularly less than or equal to 3 dB. If results from first and second tests don't fulfill the above criteria, the result from third test performed within 7 days from the second test is acceptable.
11) No significant pigmentation in ophthalmoscopic examination
12) Subjects who can give consent in writing by oneself (If subjects can not read the document because of reduction in visual function, both oral consent of the subject and signature of witness are necessary.)

Key exclusion criteria 1) HIV antibody-positive
2) Decimal visual acuities of both eyes are less than 0.1, or lateral or bilateral blindness
3) Cone-rod dystrophy
4) Interocular difference in the condition of lens
5) Co-existence of glaucoma or ocular hypertension (intraocular pressure is more than or equal to 22 mmHg)
6) Co-existence of uveitis or optic neuritis
7) Retinal or subretinal pathological change observed by fundus examination (including fluorescein fundus angiography, laser scanning fundus photography), that is independent of retinitis pigmentosa
8) Visual field measured by Goldmann perimeter V-4e is less than 10 degree at the center area of vision
9) Loss or massive structural irregularity of the layer of retinal pigment epithelium on OCT (optical coherence tomography) at the supposed site of administration
10) Having severe allergy or previous history
11) Receiving chronic hemodialysis therapy
12) Severe heart dysfunction or heart failure
13) Sever hepatic dysfunction or liver cirrhosis
14) Active inflammatory diseases
15) History of cerebral hemorrhage or infarction within 6 months before agreement
16) Hematopoietic disorders
17) Alcoholism and/or drug dependence
18) Female subjects with pregnant or doubt of pregnancy. Breast-feeding female.
19) Subjects who are diagnosed with cancer or suspected to have cancer. History of treatment of malignancies within 5 years.
20) Disapprove of birth control during at least 12 months after the administration
21) Administration of Helenien, Unoprostone, and/or Ca antagonist intended for treatment of eye disease within 30 days before agreement
22) Taking the antiviral drug at the registration
23) Plan of operation other than administration of the investigational drug during this clinical trial
24) Entry into other clinical trial and/or clinical study, or history of entry within 6 months before agreement
25) Others: Subjects who are judged to be inappropriate by principal investigator or subinvestigator
Target sample size 12

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yasuhiro Ikeda
Organization Kyushu University Hospital
Division name Department of Ophthalmology
Zip code
Address 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan
TEL 092-642-5648
Email ymocl@pathol1.med.kyushu-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yasuhiro Ikeda
Organization Kyushu University Hospital
Division name Department of Ophthalmology
Zip code
Address 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan
TEL 092-642-5648
Homepage URL
Email ymocl@pathol1.med.kyushu-u.ac.jp

Sponsor
Institute Kyushu University Hospital
Institute
Department

Funding Source
Organization AMED
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 11 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 07 Month 31 Day
Date of IRB
Anticipated trial start date
2019 Year 02 Month 14 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 09 Month 10 Day
Last modified on
2019 Year 02 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038854

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.